Granulocyte-Colony Stimulating Factor (G-CSF) May Improve Disease Outcome in Elderly Patients with Diffuse Large Cell Lymphoma (DLCL) Treated with CHOP Chemotherapy
Authors:
- Jill GlassmanJGJill Glassman
- Carol LongCLCarol Long
- Pilar TorresPTPilar Torres
- David J. StrausDSDavid J. Straus
- James P. O'BRienJOJames P. O'BRien
- Joseph BertinoJBJoseph Bertino
- Craig H. MoskowitzCMCraig H. Moskowitz
- Andrew D. ZelenetzAZAndrew D. Zelenetz
- Carol S. PortlockCPCarol S. Portlock
- 1 January 2000
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 39 (1-2) , 67-75
Abstract
Advanced age is an adverse prognostic factor in patients with DLCL. CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) has frequent dose-limiting toxicities, including myelosuppression. We retrospectively reviewed 50 consecutive patients > 60 years of age (median age 72) with B-cell DLCL who received CHOP with G-CSF. Patients received CHOP (median 6 cycles) at three-week intervals. G-CSF was given following all cycles of chemotherapy ("prophylactic G-CSF") in 28 of 50 patients, and following an episode of febrile neutropenia and thereafter in 19 patients, according to ASCO guidelines. Dose intensity, treatment delays, episodes of febrile neutropenia, complete response (CR) rate, disease-free survival, time-to-treatment failure, and overall survival were all analyzed according to the age-adjusted International Prognostic Index (aaIPI). The actual dose intensity for cyclophosphamide was 225.9 mg/m2/week and 0.90, respectively and for doxorubicin was 14.9 mg/m2/week (90% of ideal CHOP dosing for both drugs). Median followup was 4 years for the patients still living. Treatment delays and episodes of febrile neutropenia were less frequent among patients receiving G-CSF with all cycles of CHOP. The CR rates were 100%, 81%, 85%, and 36% for the low, low-intermediate, high-intermediate, and high aalPI risk groups, respectively. The 5-year actuarial relapse-free and overall survival for our patients were comparable to that of the cohort < or = 60 years of age and superior to the > 60 years of age cohort used to establish the aaIPI. With optimization of CHOP dosing, advanced age may not be an adverse prognostic factor for patients with DLCL. The routine use of G-CSF in elderly patients with DLCL should be further investigated.Keywords
This publication has 22 references indexed in Scilit:
- Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.Journal of Clinical Oncology, 1995
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1988
- Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphomaThe American Journal of Medicine, 1987
- Aggressive Chemotherapy for Diffuse Histiocytic Lymphoma in the Elderly: Increased Complications with Advancing AgeJournal of the American Geriatrics Society, 1984
- Treatment of advanced diffuse histiocytic lymphoma: An analysis of prognostic variablesCancer, 1982
- Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphomaBlood, 1981
- Factors Predicting for Response and Survival in Adults With Advanced Non-Hodgkin's LymphomaArchives of internal medicine (1960), 1978
- Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapyThe American Journal of Medicine, 1977
- Multivariate analysis of prognostic factors in the non-Hodgkin's malignant lymphomasCancer, 1974